SCHEMBL6033291

SCHEMBL6033291

Cc1c(Cl)ncnc1-c1ccc2nccnc2c1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MTOR P42345 2/20 0.44
PIK3CA P42336 2/20 0.44
PIK3CD O00329 1/20 0.44
ABL1 P00519 1/20 0.44
EGFR P00533 1/20 0.44
HCK P08631 1/20 0.44
SRC P12931 1/20 0.44
KDR P35968 1/20 0.44
PIK3CB P42338 1/20 0.44
PIK3CG P48736 1/20 0.44
EPHB4 P54760 1/20 0.44
PRKDC P78527 1/20 0.44
KMO O15229 1/20 0.41
TGFBR1 P36897 15/20 0.41
MAPK14 Q16539 3/20 0.37
FLT3 P36888 1/20 0.33
GSK3B P49841 1/20 0.33
TGFBR2 P37173 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6033768 0.82 ALDH1A1 (0.49) MTORPIK3CAPIK3CDABL1EGFR
SCHEMBL14742017 0.78 KMO (0.63) ABL1SRCKMO
SCHEMBL5646419 0.75 L3MBTL1 (0.46) MTORABL1EGFRSRCKDR
SCHEMBL5648158 0.75 SMN1; SMN2 (0.41) ABL1EGFRHCKSRCKDR
SCHEMBL27700674 0.74 MTOR (0.37) MTORPIK3CAPIK3CDABL1EGFR
SCHEMBL22211542 0.73 PTGS1 (0.45) KMO
SCHEMBL29983576 0.73 KMT2A (0.45) MTORPIK3CAPIK3CDPIK3CBPIK3CG
SCHEMBL604021 0.72 ADORA2A (0.46) MTORPIK3CASRCKMO
SCHEMBL5647677 0.70 ALDH1A1 (0.50) MTORPIK3CAPIK3CDABL1EGFR
SCHEMBL8337311 0.70 NPC1 (0.52) TGFBR1FLT3GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101035780-A Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain MERCK SHARP & DOHME (GB) 2007-09-12 CN disclosed
EP-1685124-A1 SUBSTITUTED NITROGEN-CONTAINING SIX-MEMBERED AMINO-HETEROCYCLES AS VANILLOID-1 RECEPTOR ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME LTD. (GB) 2006-08-02 EP disclosed
US-20050197342-A1 Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain HOLLINGWORTH GREGORY J (GB) 2005-09-08 US disclosed
WO-2005047279-A1 SUBSTITUTED NITROGEN-CONTAINING SIX-MEMBERED AMINO-HETEROCYCLES AS VANILLOID-1 RECEPTOR ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME LIMITED (GB) 2005-05-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197342-A1 Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain OPRL1, OPRK1, CNR1 MTOR 3792/4885PIK3CA 2679/4885PIK3CD 2932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.